FilingReader Intelligence
Everest Medicines raises HK$1.57bn through share placing
July 24, 2025 at 11:49 PM UTC•By FilingReader AI
Everest Medicines will raise gross proceeds of approximately HK$1.57bn through placing 22.6m existing shares and a concurrent top-up subscription at HK$69.70 per share, representing a 10.12% discount to the previous closing price.
Net proceeds of HK$1.55bn will fund global R&D (50%), commercialization efforts (40%), and working capital (10%).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1952•Hong Kong Exchange
News Alerts
Get instant email alerts when Everest Medicines publishes news
Free account required • Unsubscribe anytime